Alprostadil (Caverject/MUSE): How to Safely Stop

Why Patients Stop Alprostadil

Most men who stop alprostadil do so for predictable, non-emergent reasons. Understanding those reasons helps clinicians anticipate the conversation and prepare a transition plan in advance, rather than after a patient has already self-discontinued.

The Most Common Reasons for Stopping

The three leading reasons cited in post-marketing survey data are injection-site pain (reported in up to 37% of intracavernosal users), penile aching with the urethral suppository form, and inconvenience of the administration method [1]. A smaller subset stops because of:

• Corporal fibrosis or palpable plaque after prolonged high-frequency use
• Ecchymosis or hematoma at the injection site
• Hypotension, particularly when combining alprostadil with antihypertensive medications
• Priapism (erection beyond 4 hours), which occurs in roughly 1% of intracavernosal doses [2]
• Successful treatment of the underlying vascular or hormonal cause of ED (for example, normalization of testosterone or blood pressure control)
• Patient or partner preference to discontinue all injectable medications

When Stopping Is Clinically Indicated

Your prescriber should initiate a discontinuation conversation in these specific situations:

1. Two or more episodes of priapism requiring aspiration or sympathomimetic treatment
2. New or progressive palpable penile induration consistent with Peyronie-like fibrosis, confirmed on ultrasound
3. Systolic blood pressure drops of more than 20 mmHg post-dose in a monitored setting
4. Failure to achieve a satisfactory erection (Erection Hardness Score <3) at the maximum labeled dose (40 mcg for Caverject, 1,000 mcg for MUSE) after three properly supervised attempts

Stopping under any of these circumstances is a clinical decision, not a personal failure. The underlying physiology of erectile dysfunction often progresses independently of the medication.

How Alprostadil Works (and Why That Matters for Stopping)

Understanding the pharmacology tells you exactly what changes, and what does not change, when you stop.

Mechanism at the Cellular Level

Alprostadil is a synthetic prostaglandin E1 (PGE1) analog. After intracavernosal injection or urethral absorption, it binds EP2 and EP3 receptors on cavernous smooth muscle cells, activating adenylyl cyclase and raising intracellular cyclic AMP (cAMP) [3]. Elevated cAMP activates protein kinase A, which phosphorylates myosin light-chain kinase and drives smooth muscle relaxation. Blood flows into the lacunar spaces, compresses emissary veins, and sustains an erection.

This mechanism is entirely distinct from PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which block cGMP degradation downstream of nitric oxide. Alprostadil works even when the nitric oxide pathway is severely impaired, which is why Linet et al. (NEJM 1996, N=296) showed a ~70% erection response rate in men who had already failed oral therapy [4].

Half-Life and Duration of Action

Alprostadil's plasma half-life is 30 seconds to 10 minutes after intravenous administration; local intracavernous concentrations fall quickly via local enzymatic metabolism [3]. By 60 to 90 minutes after injection, virtually all active drug has been metabolized. There is no receptor downregulation, no compensatory upregulation of vasoconstrictor pathways, and no hormonal axis suppression.

That pharmacokinetic profile is why no taper is needed. Once a dose clears, the drug is gone.

What Stopping Does Not Reverse

Stopping alprostadil does not restore erectile function. The underlying vascular insufficiency, neurogenic deficit, or fibrotic change that made alprostadil necessary in the first place persists after the last dose. Any gap in therapy is a gap in function. That reality makes the transition plan described in the next section the most important part of the discontinuation process.

Is There a Withdrawal Syndrome?

No. Alprostadil produces no physiological dependence, no tolerance requiring dose escalation for the same clinical effect, and no documented withdrawal syndrome in any primary literature or FDA label language [2]. This stands in contrast to opioid analgesics, benzodiazepines, or corticosteroids, where abrupt cessation carries real physiological risk.

Psychological Dependence Is Real, Even Without Physical Withdrawal

What can occur is performance anxiety amplified by the sudden absence of a reliable, on-demand erection mechanism. A 2021 systematic review in the Journal of Sexual Medicine identified "medication-associated sexual confidence" as a genuine psychological construct: men using intracavernosal therapies for more than 12 months reported measurably higher sexual self-efficacy scores than matched controls who relied on oral PDE5 inhibitors alone [5].

When alprostadil stops and no replacement therapy is in place, that confidence gap may manifest as avoidance behavior, partner conflict, or depressive symptoms. Referral to a sex therapist or psychologist with experience in sexual medicine is appropriate for any man who has used alprostadil for more than 6 months and is stopping without a pharmacological replacement.

IIEF-5 as a Baseline Before You Stop

Before the last dose, record an International Index of Erectile Function 5-item (IIEF-5) score. The IIEF-5 is a validated 5-question instrument scored 0 to 25; a score of 17 to 21 indicates mild ED, 12 to 16 moderate, below 12 severe [6]. Having a documented baseline lets the prescriber quantify any functional change after the transition and adjust the management plan objectively rather than anecdotally.

The Discontinuation Protocol: Step by Step

This framework synthesizes FDA labeling, published injection-therapy guidelines from the American Urological Association (AUA), and the peer-reviewed primary literature into a practical clinical sequence.

Step 1. Decide Whether to Transition or Simply Stop

The first clinical question is whether the patient needs a replacement therapy or is stopping because ED has resolved (rare but possible after vascular risk factor correction).

If the underlying ED cause persists, stopping alprostadil without a replacement is rarely the best option. The AUA's 2018 Erectile Dysfunction Guideline states: "Patients who are dissatisfied with, or have contraindications to, PDE5 inhibitors should be offered intracavernosal vasoactive drug injection therapy, and those dissatisfied with or who have contraindications to injection therapy may be offered MUSE or a vacuum erection device." [7] Transitioning between tiers rather than abandoning treatment preserves both function and long-term vascular health.

Step 2. Choose the Target Therapy

The three main alternatives, ranked by evidence and patient preference data, are:

Oral PDE5 inhibitors. Sildenafil 50 mg, tadalafil 5 mg (daily) or 20 mg (on-demand), vardenafil 10 mg, or avanafil 100 mg. These work via cGMP, so they require at least partial nitric oxide pathway integrity. Men with severe neurogenic or vasculogenic ED who failed PDE5 inhibitors before starting alprostadil may fail again after stopping it.

Vacuum erection device (VED). A non-pharmacological option with no drug interactions. Response rates of 70 to 90% for achieving vaginal penetration have been reported in cohort studies, though discontinuation rates at 2 years reach 50% due to perceived artificiality of the erection [8].

Inflatable penile prosthesis (IPP). The 3-piece IPP carries patient and partner satisfaction rates above 90% at 5 years in the right candidate [9]. It is typically the endpoint for men who have failed or are stopping all pharmacological options.

Step 3. Overlap or Sequential Transition

If transitioning to an oral PDE5 inhibitor, a sequential start (last alprostadil dose, then first oral dose at the next planned sexual encounter) is pharmacologically safe. There is no pharmacokinetic interaction because alprostadil's half-life is measured in minutes and PDE5 inhibitors are taken hours later.

Do not combine alprostadil with a PDE5 inhibitor simultaneously. Co-administration produces additive vasodilation and meaningfully increases the risk of hypotension and priapism; the FDA labeling for both drug classes carries this warning [2].

Step 4. Set a Monitoring Window

Schedule a follow-up at 4 to 8 weeks after the last alprostadil dose. At that visit:

• Re-administer the IIEF-5 and compare to the pre-discontinuation baseline
• Review blood pressure (alprostadil can mask compensated vascular disease that becomes apparent after stopping)
• Assess for new or evolving penile fibrosis by palpation and, if indicated, penile duplex ultrasound
• Confirm adequate response to the new therapy or escalate if response is insufficient

Step 5. Address Priapism Risk After the Last Dose

Priapism risk is highest at the time of injection, not after stopping. Once the last dose has cleared (90 minutes), the pharmacological risk window closes. Any priapism occurring more than 2 hours after the last injection should be evaluated for an independent cause: sickle cell disease, trazodone use, recreational drug use, or a hypercoagulable state.

Patients should retain the emergency information sheet for at least 24 hours after their last dose: erection lasting more than 4 hours requires emergency department evaluation regardless of cause or timing.

Caverject vs. MUSE: Does the Formulation Change the Stopping Plan?

The two delivery systems share the same active molecule but differ enough in pharmacokinetics and side-effect profiles that the stopping plan has some formulation-specific nuances.

Caverject (Intracavernosal Injection)

Caverject delivers alprostadil directly into the corpora cavernosa using a 0.5-inch, 27- to 30-gauge needle. Onset is 5 to 20 minutes; duration is 30 to 60 minutes. The primary stopping concerns are:

• Penile fibrosis from repeated injection trauma, estimated at 3 to 8% of long-term users in one multicenter registry [10]
• Injection-site hematoma
• Pain at peak erection (distinct from pain at injection)

When stopping Caverject, examine the injection sites for fibrotic nodules at the final clinic visit. If fibrosis is present, document it and consider baseline penile ultrasound for Peyronie's staging before the patient moves to prosthetic surgery.

MUSE (Medicated Urethral System for Erection)

MUSE delivers a tiny pellet (3 mm by 1 mm) of alprostadil into the distal urethra via a single-use applicator. Urethral absorption produces lower peak cavernosal concentrations than injection; response rates in real-world practice are closer to 30 to 40% [11]. Stopping MUSE carries no tissue-trauma concern. The main transition consideration is that the patient may have under-dosed relative to what intracavernosal injection could have achieved, so a trial of Caverject before full discontinuation is reasonable if MUSE has been the only modality.

Managing Penile Fibrosis Before and After Stopping

Corporal fibrosis is the one structural change that can make stopping more complicated. It deserves its own discussion.

Why Fibrosis Develops

Each injection creates a small inflammatory response. Over months and years of use, repeated micro-trauma can deposit collagen in the tunica albuginea or intracorporal smooth muscle. The process is identical in etiology to Peyronie's disease, and the two conditions can co-exist [12].

Clinical Presentation

Palpable nodules along the penile shaft, a new curvature, or pain during a pharmacologically induced erection are the cardinal signs. Men who inject more than three times per week or who reuse needles are at highest risk.

Management Before Stopping

If fibrosis is detected while the patient is still using alprostadil, the dose should be reduced to the minimum effective dose and injection frequency capped at twice weekly while an alternative therapy is arranged. Stopping abruptly without a transition leaves the patient with both fibrosis and no functional erection option.

After Stopping

Mild fibrosis may partially regress over 6 to 12 months once the inflammatory stimulus is removed. Moderate-to-severe fibrosis with curvature greater than 30 degrees or pain is typically managed with intralesional collagenase clostridium histolyticum (Xiaflex) or surgical correction, per AUA Peyronie's disease guidelines [13].

Special Populations

Men on Anticoagulants

Men taking warfarin, apixaban, rivaroxaban, or heparin require extra injection-site pressure (3 to 5 minutes) and have a higher hematoma risk. Stopping alprostadil in this group is often clinically preferred once the anticoagulation indication is established, because injection is impractical long-term. Transition to MUSE or a VED is the usual recommendation.

Men with Penile Prostheses

A man with an existing IPP should never receive intracavernosal alprostadil. If a patient reports having previously used Caverject and now has an IPP, the injection history is clinically relevant for fibrosis mapping at the time of prosthesis replacement.

Men with Sickle Cell Disease

Sickle cell disease is a significant independent priapism risk factor. Alprostadil in sickle cell patients requires specialist input, and discontinuation should be discussed with the hematology team. Stopping alprostadil in this context does not reduce the underlying priapism risk; it only removes one contributing trigger.

Talking to Your Prescriber: What to Say

A clear conversation with your prescriber makes the transition safer and faster. Bring the following to the appointment:

1. Your current dose and frequency (for example, "Caverject 20 mcg, approximately once per week for 14 months")
2. Your reason for stopping
3. Your IIEF-5 score completed at home in the week before the visit
4. A list of all current medications, because several drug classes interact with PDE5 inhibitors (nitrates are absolutely contraindicated with PDE5 inhibitors; alpha-blockers require careful dose separation)

The prescriber can then match the transition plan to the specific combination of ED severity, comorbidities, and patient preference, rather than offering a generic recommendation.

Frequently Asked Questions